VCAM1 and myeloid sarcoma: The effect of fingolimod also differs from other immunosuppressive treatments for MS like monoclonal antibodies; this includes the anti-α4β1 monoclonal antibody, which blocks the molecular interaction between α4β1 and vascular cell adhesion molecule-1 (VCAM-1), thus lowering lymphocyte egress to the CNS [43].